Non-small cell lung cancer stage IIIB

24 trials 9 recruiting MedDRA PT
24 Registered trials
9 Recruiting
19 Unique sponsors
34 Unique IMPs
17 Commercial trials
Drug classes (ATC)
— ATC code not specified 8
L Oncology (ATC L) 16
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 11 substances
Kinase inhibitor 4 substances
Antibody-drug conjugate (ADC) 3 substances
Checkpoint inhibitor (PD-L1) 2 substances
Antimetabolite 2 substances
Monoclonal antibody (tumor, humanized) 2 substances
Monoclonal antibody (immune) 2 substances
Platinum compound 2 substances
Monoclonal antibody (chimeric) 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Immunosuppressant 1 substance
Monoclonal antibody 1 substance
Checkpoint inhibitor (PD-1) 1 substance
PARP inhibitor 1 substance
Phase III: 5 Phase II/III: 1 Phase II: 11 Phase I/II: 4 Phase I (Other): 2 Phase I (First in Human): 1

Filter these 24 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 24 trials

Phase III

5 trials
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    CRIZOTINIB; REPOTRECTINIB
    2023-505604-32-00 10 countries 2024 n=83
    Recruiting
  • Glaxosmithkline Research & Development Limited Commercial
    NIRAPARIB TOSILATE MONOHYDRATE; PEMBROLIZUMAB
    2023-508443-40-00 14 countries 2020 n=363 Orphan
    Ended
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB; SACITUZUMAB TIRUMOTECAN
    2023-508012-35-00 13 countries 2024 n=258
    Recruiting
  • Xcovery Holding Co. LLC Commercial
    CRIZOTINIB; X-396
    2024-513454-29-00 7 countries 2015 n=47
    Ended
  • ETOP IBCSG Partners Foundation Academic
    DURVALUMAB
    2023-508773-82-00 7 countries 2025 n=335
    Recruiting

Phase II/III

1 trial
  • BioNTech SE Commercial
    BISPECIFIC ANTIBODY AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR A AND PROGRAMMED DEATH-LIGAND 1; BNT327
    2024-515764-31-00 9 countries 2025 n=726
    Recruiting

Phase II

11 trials
  • AstraZeneca AB Commercial
    DATOPOTAMAB DERUXTECAN; DURVALUMAB; FALBIKITUG; INFLIXIMAB; MONALIZUMAB; MYCOPHENOLATE MOFETIL; OLECLUMAB; RILVEGOSTOMIG; VOLRUSTOMIG
    2023-508852-21-00 7 countries 2022 n=493
    Recruiting
  • Celgene Corp. Commercial
    AZACITIDINE
    2024-513405-31-00 1 country 2015 n=1
    Ended
  • Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Commercial
    DURVALUMAB
    2024-513948-28-00 1 country 2020 n=57
    Ended
  • Incyte Corp. Commercial
    INCB099280
    2022-502716-37-00 3 countries 2023 n=70
    Ended
  • Seagen Inc. Commercial
    PEMBROLIZUMAB; TISOTUMAB VEDOTIN
    2023-503812-34-00 4 countries 2019 n=79
    Ended
  • AIO-Studien gGmbH Academic
    SACITUZUMAB GOVITECAN; ZIMBERELIMAB
    2024-517561-16-00 1 country n=50
    Pending
  • Intergroupe Francophone De Cancerologie Thoracique Academic
    ATEZOLIZUMAB
    2022-502103-30-00 1 country 2023 n=156
    Ended
  • Intergroupe Francophone De Cancerologie Thoracique Academic
    BRIGATINIB; CARBOPLATIN; PEMETREXED
    2023-510387-13-00 1 country 2022 n=110
    Ended
  • Intergroupe Francophone De Cancerologie Thoracique Academic
    LORLATINIB
    2024-512028-12-00 1 country 2021 n=84
    Ended
  • Intergroupe Francophone De Cancerologie Thoracique Academic
    IMP not specified
    2025-522790-10-00 1 country n=108
    Pending
  • Universita' Degli Studi Di Torino Academic
    PEMBROLIZUMAB
    2024-514701-57-01 1 country n=126
    Pending

Phase I/II

4 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    BUDIGALIMAB; CARBOPLATIN; CISPLATIN; PEMBROLIZUMAB; PEMETREXED; TELISOTUZUMAB ADIZUTECAN
    2024-514465-18-00 7 countries 2025 n=96
    Recruiting
  • BioNTech SE Commercial
    BNT326; BNT327
    2024-519344-32-00 4 countries 2026 n=88
    Recruiting
  • BioNTech SE Commercial
    BNT324; BNT327
    2024-520238-31-01 4 countries 2026 n=112 Orphan
    Recruiting
  • Galecto Biotech AB Commercial
    5-BROMOPYRIDIN-3-YL 3-DEOXY-1-THIO-3-[4-(3,4,5-TRIFLUOROPHENYL)-1H-1,2,3-TRIAZOL-1-YL]-ALFA-D-GALACTOPYRANOSIDE; ATEZOLIZUMAB
    2024-514419-93-00 2 countries 2022 n=49
    Ended

Phase I (Other)

2 trials
  • Systimmune Inc. Commercial
    IMP not specified
    2023-506539-14-00 3 countries 2025 n=95
    Recruiting
  • TOLREMO therapeutics AG Commercial
    IMP not specified
    2024-519071-25-00 1 country n=40
    Pending

Phase I (First in Human)

1 trial
  • Achilles Therapeutics UK Limited Commercial
    ATL001; PEMBROLIZUMAB
    2024-513060-26-00 3 countries 2021 n=24
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Intergroupe Francophone De Cancerologie Thoracique Academic 4 Phase II 0
BioNTech SE Commercial 3 Phase II/III, Phase I/II 3
Systimmune Inc. Commercial 1 Phase I (Other) 1
TOLREMO therapeutics AG Commercial 1 Phase I (Other) 0
AstraZeneca AB Commercial 1 Phase II 1
Celgene Corp. Commercial 1 Phase II 0
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Commercial 1 Phase II 0
Incyte Corp. Commercial 1 Phase II 0
Seagen Inc. Commercial 1 Phase II 0
Bristol-Myers Squibb Services Unlimited Company Commercial 1 Phase III 1
Glaxosmithkline Research & Development Limited Commercial 1 Phase III 0
Merck Sharp & Dohme LLC Commercial 1 Phase III 1
Xcovery Holding Co. LLC Commercial 1 Phase III 0
Achilles Therapeutics UK Limited Commercial 1 Phase I (First in Human) 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase I/II 1
Galecto Biotech AB Commercial 1 Phase I/II 0
AIO-Studien gGmbH Academic 1 Phase II 0
Universita' Degli Studi Di Torino Academic 1 Phase II 0
ETOP IBCSG Partners Foundation Academic 1 Phase III 1
New trials by year
2019
1
2020
2
2021
2
2022
3
2023
2
2024
2
2025
4
2026
2
← All indication landscapes